Article Text

PDF
Rosuvastatin prevented major cardiovascular events in people with elevated C-reactive protein

Statistics from Altmetric.com

P M Ridker

Dr P M Ridker, Brigham and Women’s Hospital, Boston, MA, USA; pridker@partners.org

STUDY DESIGN

Design:

randomised placebo-controlled trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin [JUPITER]). ClinicalTrials.gov NCT00239681.

Allocation concealment:

concealed.*

Blinding:

blinded (patients, clinicians, data collectors, and outcome adjudication committee).*

STUDY QUESTION

Setting:

1315 sites in 26 countries.

Patients:

17 802 men ⩾50 years of age or women ⩾60 years of age (mean age 66 y, 62% men) who had no history of cardiovascular (CV) disease, high-sensitivity C-reactive protein concentrations ⩾2.0 mg/l, low-density lipoprotein cholesterol levels <3.4 mmol/l (130 mg/dl), and triglyceride concentrations <5.6 mmol/l (500 mg/dl). …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.